Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial
Abstract Background The treatments for refractory leptomeningeal metastasis (RLM) of non-small cell lung cancer (NSCLC) are limited, and response assessment is complex and challenging. This clinical trial aimed to evaluate the efficacy of intrathecal pemetrexed (IP) and response assessment using cer...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-025-04134-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849705042330779648 |
|---|---|
| author | Qingsheng Xu Kaiyuan Huang Luqing Tong Danfang Yan Yilei Zhao Hanjin Yang Weili Jin Luyuan Zhang Jinquan Cai Qun Chen |
| author_facet | Qingsheng Xu Kaiyuan Huang Luqing Tong Danfang Yan Yilei Zhao Hanjin Yang Weili Jin Luyuan Zhang Jinquan Cai Qun Chen |
| author_sort | Qingsheng Xu |
| collection | DOAJ |
| description | Abstract Background The treatments for refractory leptomeningeal metastasis (RLM) of non-small cell lung cancer (NSCLC) are limited, and response assessment is complex and challenging. This clinical trial aimed to evaluate the efficacy of intrathecal pemetrexed (IP) and response assessment using cerebrospinal fluid (CSF) tumor marker in RLM. Methods This was a single-center, single-arm, phase II adaptive clinical trial. Patients with RLM of NSCLC were eligible for inclusion. Patients were assigned to receive 30 mg of IP every 3 weeks for a total of 6 cycles. The primary endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS) evaluated according to EANO-ESMO response assessment, disease control rate, the concordance of CSF tumor marker response with EANO-ESMO response assessment, and safety. Results A total of 29 patients were enrolled in the trial. The median PFS was 10.03 months (95% CI, 6.42–13.64), and the median OS was 20.37 months (95% CI, 14.86–25.88), respectively. A ± 35% threshold for CSF tumor marker level change (TML) yielded the optimal predictive performance, with AUCs of 0.890 (95% CI, 0.833–0.947), 0.911 (95% CI, 0.870–0.951), and 0.784 (95% CI, 0.717–0.850) for EANO-ESMO response, progression, and stable, respectively. Most patients (93.1%) experienced grade 1–2 treatment-related adverse events. Conclusions Our therapeutic regimen of IP provided a practical, survival-extending, and tolerant option for RLM patients. CSF tumor marker response was correlated with EANO-ESMO response assessment, offering an effective tool for response monitoring of RLM. Trial registration Chinese Clinical Trial Register (ChiCTR) ChiCTR2200057235. Registered on March 1, 2022. Date of the first patient enrollment: April 29, 2022. |
| format | Article |
| id | doaj-art-a3fbde03f4db4e3095c75ba73d48ea16 |
| institution | DOAJ |
| issn | 1741-7015 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medicine |
| spelling | doaj-art-a3fbde03f4db4e3095c75ba73d48ea162025-08-20T03:16:34ZengBMCBMC Medicine1741-70152025-05-0123111210.1186/s12916-025-04134-7Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trialQingsheng Xu0Kaiyuan Huang1Luqing Tong2Danfang Yan3Yilei Zhao4Hanjin Yang5Weili Jin6Luyuan Zhang7Jinquan Cai8Qun Chen9Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Radiology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of MedicineThe Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of MedicineAbstract Background The treatments for refractory leptomeningeal metastasis (RLM) of non-small cell lung cancer (NSCLC) are limited, and response assessment is complex and challenging. This clinical trial aimed to evaluate the efficacy of intrathecal pemetrexed (IP) and response assessment using cerebrospinal fluid (CSF) tumor marker in RLM. Methods This was a single-center, single-arm, phase II adaptive clinical trial. Patients with RLM of NSCLC were eligible for inclusion. Patients were assigned to receive 30 mg of IP every 3 weeks for a total of 6 cycles. The primary endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS) evaluated according to EANO-ESMO response assessment, disease control rate, the concordance of CSF tumor marker response with EANO-ESMO response assessment, and safety. Results A total of 29 patients were enrolled in the trial. The median PFS was 10.03 months (95% CI, 6.42–13.64), and the median OS was 20.37 months (95% CI, 14.86–25.88), respectively. A ± 35% threshold for CSF tumor marker level change (TML) yielded the optimal predictive performance, with AUCs of 0.890 (95% CI, 0.833–0.947), 0.911 (95% CI, 0.870–0.951), and 0.784 (95% CI, 0.717–0.850) for EANO-ESMO response, progression, and stable, respectively. Most patients (93.1%) experienced grade 1–2 treatment-related adverse events. Conclusions Our therapeutic regimen of IP provided a practical, survival-extending, and tolerant option for RLM patients. CSF tumor marker response was correlated with EANO-ESMO response assessment, offering an effective tool for response monitoring of RLM. Trial registration Chinese Clinical Trial Register (ChiCTR) ChiCTR2200057235. Registered on March 1, 2022. Date of the first patient enrollment: April 29, 2022.https://doi.org/10.1186/s12916-025-04134-7Intrathecal pemetrexedResponse assessmentTumor marker in cerebrospinal fluidRefractory leptomeningeal metastasisNon-small-cell lung cancer |
| spellingShingle | Qingsheng Xu Kaiyuan Huang Luqing Tong Danfang Yan Yilei Zhao Hanjin Yang Weili Jin Luyuan Zhang Jinquan Cai Qun Chen Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial BMC Medicine Intrathecal pemetrexed Response assessment Tumor marker in cerebrospinal fluid Refractory leptomeningeal metastasis Non-small-cell lung cancer |
| title | Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial |
| title_full | Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial |
| title_fullStr | Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial |
| title_full_unstemmed | Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial |
| title_short | Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial |
| title_sort | intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non small cell lung cancer a single arm phase ii trial |
| topic | Intrathecal pemetrexed Response assessment Tumor marker in cerebrospinal fluid Refractory leptomeningeal metastasis Non-small-cell lung cancer |
| url | https://doi.org/10.1186/s12916-025-04134-7 |
| work_keys_str_mv | AT qingshengxu intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT kaiyuanhuang intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT luqingtong intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT danfangyan intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT yileizhao intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT hanjinyang intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT weilijin intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT luyuanzhang intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT jinquancai intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial AT qunchen intrathecalpemetrexedefficacyandcerebrospinalfluidtumormarkerresponseinrefractoryleptomeningealmetastasisofnonsmallcelllungcancerasinglearmphaseiitrial |